Skip to content
Erudio Health
menu
Clinical trial · no report yet · Phase not applicable

TRANSMET

Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases Treated by Chemotherapy

  • NCT02597348 ↗
  • Unknown
  • Assistance Publique - Hôpitaux de Paris
  • 127 commentary sources found
  • Deep

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Commentary we found

Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.

ChannelFound
X threads78
YouTube25
Podcasts22
X videos2

The trial

ClinicalTrials.gov
Official title
Curative Potential of Liver Transplantation in Patients With Definitively Unresectable Colorectal Liver Metastases (CLM) Treated by Chemotherapy: a Prospective Multicentric Randomized Trial
Phase
Phase not applicable
Status
Unknown
Conditions
Liver Metastasis; Colorectal Cancer; Metastasis
Interventions
Liver Transplantation
Arms
  • Liver Transplantation · Experimental
  • No intervention · No intervention
Enrollment
94
Primary outcomes
  • 5 years overall survival (OS)
Sponsor
Assistance Publique - Hôpitaux de Paris
Start
Feb 2016
Primary completion
Jul 2026 (estimated)
Results posted
No
Registry record
NCT02597348 · updated Feb 14, 2024

Publications

linked from the registry
  • Adam R, Piedvache C, Chiche L, Adam JP, Salame E, Bucur P, Cherqui D, Scatton O, Granger V, Ducreux M, Cillo U, Cauchy F, Mabrut JY, Verslype C, Coubeau L, Hardwigsen J, Boleslawski E, Muscari F, Jeddou H, Pezet D, Heyd B, Lucidi V, Geboes K, Lerut J, Majno P, Grimaldi L, Levi F, Lewin M, Gelli M; Collaborative TransMet group. Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. Lancet. 2024 Sep 21;404(10458):1107-1118. doi: 10.1016/S0140-6736(24)01595-2. PubMed 39306468